Skip to main content

Table 1 Baseline demographics

From: Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial

 

Low-NED (≤ 0.25 µg/kg/min)

p-value

High-NED (> 0.25 µg/kg/min)

p-value

Placebo (n = 48)

AT II (n = 56)

Placebo (n = 110)

AT II (n = 107)

Age (yrs)

65.0 (50–75)

63.0 (53–73)

0.91

65.0 (53–75)

63.0 (51–75)

0.78

Female sex, n (%)

21 (43.8)

21 (37.5)

0.55

34 (30.9)

50 (46.7)

0.02

BMI (kg/m2)

31.0 (25.5–37.6)

28.8 (23.9–35.4)

0.18

28.4 (23.6–34.2)

28.1 (24.2–32.9)

0.62

Hypertension, n (%)

29 (60.4)

37 (66.1)

0.68

58 (52.3)

61 (56.5)

0.59

Exposure to ACE inhibitors, n (%)

6 (12.5)

6 (10.7)

1.00

9 (8.2)

9 (8.4)

1.00

Exposure to ARBs, n (%)

5 (10.4)

5 (8.9)

1.00

6 (5.5)

6 (5.6)

1.00

APACHE II score

27.0 (20–34)

27.0 (20–33)

0.81

29.5 (24–34)

27.0 (23–33)

0.14

SOFA score

12 (10–13)

12 (10–14)

0.55

13 (11–15)

12 (10–13)

 < 0.001

Cardiac index (L/min/m2)*

3.2 (2.7–4.3)

3.0 (2.5–3.8)

0.25

3.2 (2.6–3.9)

3.0 (2.6–3.8)

0.68

Lactate (mmol/L)

2.2 (1.2–3.6)

2.4 (1.5–3.3)

0.67

4.1 (2.2–8.2)

3.1 (2.1–5.6)

0.07

Chest X-ray finding of ARDS, n (%)

13 (27.1)

11 (19.6)

0.48

38 (34.5)

29 (27.4)

0.30

MAP (mmHg)

67.3 (65.7–68.9)

67.5 (65.3–69.7)

0.94

65.7 (62.0–68.0)

65.7 (63.3–68.7)

0.28

NED (µg/kg/min)

0.21 (0.19–0.23)

0.21 (0.18–0.23)

0.45

0.45 (0.34–0.70)

0.47 (0.33–0.68)

0.75

Vasopressin use in the 6 h prior to randomization, n (%)†

30 (62.5)

34 (60.7)

1.00

81 (73.6)

79 (73.8)

1.00

Steroid use, n (%)

14 (29.2)

10 (17.9)

0.24

34 (30.9)

28 (26.2)

0.46

Receiving RRT, n (%)

9 (18.8)

17 (30.4)

0.26

54 (49.1)

31 (29.0)

0.003

Angiotensin I (pg/ml)

171.5 (64.0–446.0)

240.5 (55.8–558.0)

0.75

257.0 (77.9–828.0)

285.0 (87.4–869.0)

0.73

Angiotensin II (pg/ml)

80.5 (25.4–345.0)

72.1 (16.9–203.0)

0.41

64.9 (16.7–342.0)

116.0 (32.2–257.0)

0.33

Angiotensin I:II ratio

1.2 (0.7–2.9)

1.3 (0.8–7.4)

0.26

2.0 (1.1–5.8)

1.7 (1.0–4.8)

0.66

Renin (pg/ml)

65.6 (33.5–197.1)

138.8 (43.6–252.4)

0.23

285.8 (89.1–754.2)

153.0 (81.1–630.5)

0.20

  1. Unless otherwise noted, all values are expressed as median (IQR)
  2. ARDS, acute respiratory distress syndrome; AT II, angiotensin II; BMI, body mass index; MAP, mean arterial pressure; NED, norepinephrine-equivalent dose; RRT, renal replacement therapy
  3. *n’s for cardiac index were: 15, 24, 58, and 45 for each subgroup, respectively. For the remaining subjects, the measures of central venous oxygen saturation of greater than 70% coupled with central venous pressure of greater than 8 mmHg were used to confirm vasodilatory shock. There were no significant differences between subgroups in either of these latter measures
  4. †The use of vasopressin was not standardized and was based on the regional availability. The mean dose across subgroups was 0.04 U/min
Back to article page

Critical Care

ISSN: 1364-8535